Sofia Ernestam

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial

Ronald van Vollenhoven, Sofia Ernestam, P. Geborek et al. · The Lancet · 2009 · 316 citations

Inflammation, Rheumatology, Rheumatoid Disorder +12

Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial

Ronald van Vollenhoven, Pierre Geborek, Kristina Forslind et al. · The Lancet · 2012 · 223 citations

Rheumatoid Disorder, Rheumatology, Systemic Treatment +8

Predictors of response to methotrexate in early DMARD naïve rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial

Saedís Saevarsdóttir, Helena Wallin, Maria Seddighzadeh et al. · Annals of the Rheumatic Diseases · 2010 · 192 citations

Incidence of Rheumatoid Arthritis in Sweden: A Nationwide Population‐Based Assessment of Incidence, Its Determinants, and Treatment Penetration

Jonas Eriksson, Martin Neovius, Sofia Ernestam et al. · Arthritis Care & Research · 2012 · 174 citations

Adalimumab (Humira®) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade®) or etanercept (Enbrel®): results from the STURE registry at Karolinska University Hospital

Marius C. Wick, Sofia Ernestam, Staffan Lindblad et al. · Scandinavian Journal of Rheumatology · 2005 · 119 citations